Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016 Life Science Investing
Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis Life Science Investing
CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial Life Science Investing
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation Life Science Investing
Takeda to develop Zika Vaccine with up to $312 million in funding from US Government Life Science Investing
Cynapsus Therapeutics Up 115% on US$624 million Acquisition by Sunovion Pharmaceuticals Pharmaceutical Investing
